Oral β-glucan and vaccine response in individuals with metastatic neuroblastoma

  • Individuals with high-risk relapsed metastatic neuroblastoma set to receive the GD2/3 vaccine were split into two groups to assess the effect of oral β-glucan during vaccine priming.
  • The addition of oral β-glucan during vaccine priming resulted in a higher stimulated IgG antibody response (P=0.08) with no toxic adverse effects, however; there were no differences in seroconversion rates between groups
  • The authors concluded that while IgG antibody response is increased, this does not directly lead to increased seroconversion so further research is required for oral β-glucan to have direct clinical implications.